Strides Pharma Science Limited reported its Q3 FY25 financial performance with strong year-on-year (YoY) revenue growth and a significant improvement in net profit. The company’s revenue from operations increased to Rs 1,154 crore, up 15% from Rs 1,006 crore in Q3 FY24. Sequentially, revenue saw a slight dip from Rs 1,167 crore in Q2 FY25 due to fluctuations in operational output.
The company’s total income stood at Rs 1,159 crore for the quarter, compared to Rs 1,014 crore YoY. Total expenses amounted to Rs 1,044 crore, a 6% increase from Rs 983 crore in Q3 FY24, driven by higher costs of materials consumed and other operating expenses. Despite rising costs, Strides Pharma’s profit before tax improved to Rs 112 crore in Q3 FY25, compared to a loss of Rs 22 crore YoY. The company’s net profit after tax surged to Rs 90 crore, a significant turnaround compared to Rs 5 crore in Q3 FY24 and Rs 72 crore in Q2 FY25.
Key expenses included Rs 477 crore for materials consumed, up 63% YoY, and Rs 215 crore for employee benefits. Depreciation expenses were stable at Rs 48 crore, and finance costs increased to Rs 52 crore compared to Rs 29 crore a year ago. Strides Pharma attributed its strong net profit performance to operational efficiencies, cost management, and improved business execution across key segments.
Strides Pharma’s outlook remains positive, with ongoing efforts in expanding its portfolio and operational footprint across geographies. The company emphasized its focus on delivering sustainable growth and shareholder value.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
